Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

burosumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Nevus, Sebaceous of Jadassohn × Clear all
NCT05195762 2024-05-28

12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi

Stanford University

Phase 2 Withdrawn

Nevus, Sebaceous of Jadassohn

NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT02722798 2022-09-06

A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Kyowa Kirin Co., Ltd.

Phase 2 Completed
14 enrolled

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡